Saiki, Takuya, Kawai, Tomoko, Morita, Kyoko et al. · Molecular medicine (Cambridge, Mass.) · 2008 · DOI
This study looked at blood samples from ME/CFS patients and compared the activity of genes between patients and healthy people. Researchers found 9 genes that showed different activity patterns in ME/CFS patients—genes involved in energy production, immune cell function, and protein breakdown. These 9 genes were able to correctly identify ME/CFS patients about 94% of the time, suggesting they could potentially be useful as a biological test to diagnose the condition.
ME/CFS currently lacks objective biomarkers for diagnosis, relying instead on clinical criteria. If validated in larger, independent populations, a gene expression signature could enable objective diagnostic testing and help distinguish ME/CFS from other fatigue-causing conditions. Understanding which biological pathways are altered—particularly energy metabolism and immune function—provides direction for investigating disease mechanisms.
This study does not establish that these gene expression changes cause ME/CFS or explain the underlying biological mechanisms. The cross-sectional design cannot determine whether altered gene expression precedes symptom onset, develops as a consequence of illness, or represents a secondary effect. The modest sample sizes also mean results require validation in larger, geographically diverse, independent cohorts before clinical utility can be confirmed.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →